Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that inhibits platelet activation and aggregation.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** Reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with a history of myocardial infarction (MI).
* **Secondary Prevention:** In patients with a history of MI, ticagrelor is used to reduce the rate of cardiovascular death, MI, and stroke.
## Adult Dosing
* **ACS:** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily for at least 12 months. Subsequent therapy should be based on individual patient risk assessment.
* **Secondary Prevention (post-MI):** 60 mg orally twice daily.
## Pediatric Dosing
* There is no established pediatric dosing for ticagrelor. Use in pediatric patients is not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required for mild to moderate renal impairment. In severe renal impairment, use with caution.
* **Hepatic Impairment:** No dose adjustment is required for mild to moderate hepatic impairment. Ticagrelor is contraindicated in severe hepatic impairment.
## Contraindications
* Hypersensitivity to ticagrelor or any excipient.
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Severe hepatic impairment.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including fatal and life-threatening), bradycardia.
* **Serious:** Increased risk of bleeding, ventricular pauses, angioedema, hypersensitivity reactions.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure and risk of bleeding. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease ticagrelor exposure.
* **Strong CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4, increasing the exposure of coadministered strong CYP3A4 substrates with a narrow therapeutic index (e.g., simvastatin, lovastatin). Limit statin dose.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for bradycardia, particularly in patients with risk factors.
* Consider baseline and periodic assessment of renal function.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel.
* The 180 mg loading dose for ACS is crucial for rapid platelet inhibition.
* The 60 mg twice-daily dose for secondary prevention is a lower maintenance dose than used in ACS.
* Discontinuation of ticagrelor prematurely increases the risk of thrombotic events.
* When switching from or to clopidogrel or prasugrel, consider the different durations of action and the need for a loading dose.
---
*Disclaimer: This information is intended for clinical use and should not replace professional judgment. Always consult the current prescribing information and relevant guidelines for complete details and to ensure patient safety.*
